We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva share price has risen 17.7% this year so far against the industry’s decrease of 5.9%.
Teva’s earnings performance has been mixed, with the company beating expectations in two of the past four quarters, matching estimates in one and missing the same in the remaining quarter. The four-quarter average earnings surprise is 7.23%.
Factors to Consider
In the second quarter, Teva’s branded drug sales are expected to have been hurt by generic erosion in sales of Copaxone and lower sales of Bendeka/Treanda. However, its new branded drug Austedo is expected to have provided top-line support as in the past few quarters.
Meanwhile, sales of its new CGRP, Ajovy were soft in the past few quarters. Management, in the past, had attributed the lower market share to preference of patients for auto injectors while Ajovy is available as a subcutaneous injection. Importantly, Teva’s auto injector device for Ajovy is now approved in the United States and EU and was launched in the United States in late April. We expect management to discuss how this new device has helped improve market share of the drug on the second-quarter conference call.
The Zacks Consensus Estimate for sales of Ajovy and Austedo in North America is $34.0 million and $135 million, respectively.
Teva’s new generic product launches including recently launched Truxima (biosimilar versions of Roche’s cancer drug Rituxan) and Herzuma (biosimilar to Roche’s Herceptin) are likely to have boosted sales of its Generics unit, making up for price erosion.
The Zacks Consensus Estimate for sales of Copaxone and Generic Products in North America is pegged at $178 million and $918 million, respectively.
Overall, Teva’s sales in the first quarter had benefited from greater demand in several markets for generic and OTC products and respiratory products amid the coronavirus-related lockdown. However, the stockpiling benefit seen in the first quarter is likely to have reversed in the second quarter. Meanwhile, reduced physical interaction between its sales force and physicians could have resulted in slower uptake of new products.
Importantly, on its second-quarter earnings call, investors will also focus on whether Teva makes any changes to its business outlook for 2020 to include the updated impact of coronavirus.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Teva this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Its Earnings ESP is -0.97% as the Zacks Consensus Estimate stands at 52 cents per share while the Most Accurate Estimate is 51 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Translate Bio, Inc. (TBIO - Free Report) has an Earnings ESP of +5.26% and holds a Zacks Rank of 2.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +28.42% and carries a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Teva (TEVA) to Report Q2 Earnings: What's in the Cards?
Teva Pharmaceutical Industries Limited (TEVA - Free Report) is scheduled to report second-quarter 2020 results on Aug 5, before market open.
In the last-reported quarter, the company delivered an earnings beat of 28.81%.
Teva Pharmaceutical Industries Ltd. Price and EPS Surprise
Teva Pharmaceutical Industries Ltd. price-eps-surprise | Teva Pharmaceutical Industries Ltd. Quote
Teva share price has risen 17.7% this year so far against the industry’s decrease of 5.9%.
Teva’s earnings performance has been mixed, with the company beating expectations in two of the past four quarters, matching estimates in one and missing the same in the remaining quarter. The four-quarter average earnings surprise is 7.23%.
Factors to Consider
In the second quarter, Teva’s branded drug sales are expected to have been hurt by generic erosion in sales of Copaxone and lower sales of Bendeka/Treanda. However, its new branded drug Austedo is expected to have provided top-line support as in the past few quarters.
Meanwhile, sales of its new CGRP, Ajovy were soft in the past few quarters. Management, in the past, had attributed the lower market share to preference of patients for auto injectors while Ajovy is available as a subcutaneous injection. Importantly, Teva’s auto injector device for Ajovy is now approved in the United States and EU and was launched in the United States in late April. We expect management to discuss how this new device has helped improve market share of the drug on the second-quarter conference call.
The Zacks Consensus Estimate for sales of Ajovy and Austedo in North America is $34.0 million and $135 million, respectively.
Teva’s new generic product launches including recently launched Truxima (biosimilar versions of Roche’s cancer drug Rituxan) and Herzuma (biosimilar to Roche’s Herceptin) are likely to have boosted sales of its Generics unit, making up for price erosion.
The Zacks Consensus Estimate for sales of Copaxone and Generic Products in North America is pegged at $178 million and $918 million, respectively.
Overall, Teva’s sales in the first quarter had benefited from greater demand in several markets for generic and OTC products and respiratory products amid the coronavirus-related lockdown. However, the stockpiling benefit seen in the first quarter is likely to have reversed in the second quarter. Meanwhile, reduced physical interaction between its sales force and physicians could have resulted in slower uptake of new products.
Importantly, on its second-quarter earnings call, investors will also focus on whether Teva makes any changes to its business outlook for 2020 to include the updated impact of coronavirus.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Teva this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Its Earnings ESP is -0.97% as the Zacks Consensus Estimate stands at 52 cents per share while the Most Accurate Estimate is 51 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Teva carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are some biotech stocks that have the right combination of elements to beat on earnings this time around:
AcelRx Pharmaceuticals, Inc. has an Earnings ESP of +40.74% and carries a Zacks Rank #2, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Translate Bio, Inc. (TBIO - Free Report) has an Earnings ESP of +5.26% and holds a Zacks Rank of 2.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +28.42% and carries a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>